AstraZeneca PLC (LSE:AZN) Annual Report 2021



The latest annual report of AstraZeneca PLC (AZN) was published on 31 Dec 2021. An annual report is a document that public corporations must provide annually to shareholders that describes their operations and financial conditions. Typically, an annual report will contain sections such as General corporate information, Operating and Financial highlights, Letter to shareholders from the CEO, Financial statements etc.

Key Statistics - AZN Annual Results

Amounts in USD

Total Revenue
37.42B
Gross Profit
27.61B
EBIT
4.57B
Net Tangible Assets
-23.12B
Net Income
112M
Capital Expenditures
-1.09B

AZN Income Statement 2021 Annual Report

As per the latest Income Statement of AZN, the Net revenue increased by $10.8B (41%) compared to the previous period. The operating income in 2021 increased by $421.00M (10%). The net income as per the annual report was 112M which decreased by $-3.084B (-96%) compared to previous year.

Income Statement Report (2021/2020)

2021 2020
Total Revenue 37.42B 26.62B
Gross Profit 27.61B 21.37B
Operating Income 4.57B 4.15B
Income Before Tax -265M 3.92B
Net Income 112M 3.2B

Balance Sheet - AZN 2021 Annual Report

Read further: AZN Balance Sheet Detailed Analysis

The latest balance sheet from annual result of AstraZeneca PLC showed the company reduced the cash on balance sheet by $-1.503B (-19%). The Net tangible assets of AZN on the balance sheet were at -23.12B which is $-5.946B (-35%) less than previous annual report. The total stockholder equity also increased by $23.646B (151%) compared to previous reporting period.

Balance Sheet Statement Report (2021/2020)

2021 2020
Cash 6.33B 7.83B
Total Assets 105.36B 66.73B
Long Term Debt 29.72B 19.8B
Total Liabilities 66.08B 51.09B
Total Shareholder Equity 39.27B 15.62B
Net Tangible Assets -23.12B -17.17B

Cash Flow Statement - AZN 2021 Annual Report

The 2021 annual cash flow statement of AstraZeneca PLC showed that the net income decreased by $-3.084B (-96%) compared to previous reporting period. Also the capital expenditure of AZN decreased by $-130.00M (-14%).

As of 2021, the total cash from investing activities was -11.06B and total cash from financing activities was 3.65B.

Cash Flow Statement Report (2021/2020)

2021 2020
Net Income 112M 3.2B
Capital Expenditures -1.09B -961M
Dividends Paid -3.86B -3.57B
Total Cash From From Investing Activities -11.06B -285M
Total Cash From From Financing Activities 3.65B -2.2B

AstraZeneca PLC Annual Report History

Income Statement

Income Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Total Revenue 37.42B 26.62B 24.38B 22.09B
Cost Of Revenue 9.81B 5.25B 4.85B 4.5B
Gross Profit 27.61B 21.37B 19.54B 17.59B
Research Development 8.58B 6.12B 5.35B 5.3B
Selling General Administrative 14.67B 11.59B 11.44B 10.82B
Non Recurring - - - -
Other Operating Expenses -207M -486M -319M -266M
Total Operating Expenses 32.85B 22.47B 21.32B 20.36B
Operating Income 4.57B 4.15B 3.07B 1.73B
Total Other Income Expense Net -4.83B -232M -1.52B 262M
Ebit 4.57B 4.15B 3.07B 1.73B
Interest Expense -776M -738M -780M -744M
Income Before Tax -265M 3.92B 1.55B 1.99B
Income Tax Expense -380M 772M 321M -57M
Minority Interest 19M 16M 1.47B 1.58B
Net Income From Continuing Ops 115M 3.14B 1.23B 2.05B
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect Of Accounting Charges - - - -
Other Items - - - -
Net Income 112M 3.2B 1.33B 2.15B
Net Income Applicable To Common Shares 112M 3.2B 1.33B 2.15B

Balance Sheet Statement

Balance Sheet Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Cash 6.33B 7.83B 5.37B 4.83B
Short Term Investments 53M 42M 38M 40M
Net Receivables 8.79B 5.65B 5.18B 4.84B
Inventory 8.98B 4.02B 3.19B 2.89B
Other Current Assets 556M 99M 106M 1.24B
Total Current Assets 26.24B 19.54B 15.56B 15.59B
Long Term Investments 1.26B 1.19B 1.51B 978M
Property Plant Equipment 10.17B 8.92B 8.34B 7.42B
Good Will 20B 11.85B 11.67B 11.71B
Intangible Assets 42.39B 20.95B 20.83B 21.96B
Other Assets 5.3B 4.28B 3.47B 3B
Deferred Long Term Asset Charges 4.33B 3.44B 2.72B 2.38B
Total Assets 105.36B 66.73B 61.38B 60.65B
Accounts Payable 2.82B 2.35B 1.77B 1.72B
Short Long Term Debt 2.25B 1.57B 1.63B 1.03B
Other Current Liab 4.52B 5.85B 4.9B 3.73B
Long Term Debt 29.72B 19.8B 17.89B 19.2B
Other Liab 13.01B 10.49B 10.28B 11.11B
Minority Interest 19M 16M 1.47B 1.58B
Total Current Liabilities 22.59B 20.31B 18.12B 16.29B
Total Liab 66.08B 51.09B 46.78B 46.61B
Common Stock 387M 328M 328M 317M
Retained Earnings 3.64B 6.44B 5B 7.69B
Treasury Stock 111M 881M -143M 34M
Capital Surplus 35.13B 7.97B 7.94B 4.43B
Other Stockholder Equity 111M 881M -143M 34M
Total Stockholder Equity 39.27B 15.62B 13.13B 12.47B
Net Tangible Assets -23.12B -17.17B -19.37B -21.2B

Cash Flow Statement

Cash Flow Statement history of AstraZeneca PLC (LSE:AZN)

31 Dec 2021 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net Income 112M 3.2B 1.33B 2.15B
Depreciation 4.04B 2.83B 2.71B 2.73B
Change To Netincome -272M -1.65B -802M -1.71B
Change To Account Receivables -961M -739M -898M -523M
Change To Liabilities 1.41B 1.72B 868M -103M
Change To Inventory 1.58B -621M -316M -13M
Total Cash From Operating Activities 5.96B 4.8B 2.97B 2.62B
Capital Expenditures -1.09B -961M -979M -1.04B
Investments 605M 2B 125M 140M
Other Cashflows From Investing Activities 54M 87M 274M 193M
Total Cashflows From Investing Activities -11.06B -285M -657M 963M
Dividends Paid -3.86B -3.57B -3.59B -3.48B
Net Borrowings 7.65B 1.44B -1.7B 1.47B
Other Cashflows From Financing Activities -178M -101M 4M -67M
Total Cash From Financing Activities 3.65B -2.2B -1.76B -2.04B
Effect Of Exchange Rate -62M 12M 5M -38M
Change In Cash -1.51B 2.32B 552M 1.5B
Issuance Of Stock 29M 30M 3.52B 34M